Standard Biotools (LAB) Common Equity (2010 - 2026)

Standard Biotools (LAB) has 17 years of Common Equity data on file, last reported at $561.1 million in Q1 2026.

• Quarterly Common Equity rose 23.43% year-over-year to $561.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $561.1 million (up 23.43% YoY) and the FY2025 annual result came in at $424.3 million, down 10.05% from the prior year.
• Common Equity grew to $561.1 million in Q1 2026 per LAB's latest filing, from $424.3 million in the prior quarter.
• Across five years, Common Equity topped out at $577.3 million in Q1 2024 and bottomed at -$148.1 million in Q4 2023.
• The 5-year median for Common Equity is $399.7 million (2025), against an average of $215.5 million.
• The widest annual swing landed in 2023, when Common Equity tumbled 539.35%; it then jumped 694.23% in 2024.
• Tracing LAB's Common Equity over 5 years: stood at -$81.5 million in 2022, then slumped by 81.73% to -$148.1 million in 2023, then soared by 418.62% to $471.7 million in 2024, then decreased by 10.05% to $424.3 million in 2025, then surged by 32.25% to $561.1 million in 2026.
• Per Business Quant, the three latest LAB Common Equity figures stand at $561.1 million (Q1 2026), $424.3 million (Q4 2025), and $399.7 million (Q3 2025).

Peer Comparison